author-photo

Naotoshi Sugimoto

104

Papers

3133

Citations

Citation Trend

Filter By

Papers (72) Sort By

Journal Conference Others

aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer

2019 Oncologist
Show All
- Source
- Cite
- Save
Citations (2)
A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non–small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L)

2019 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (10)
Evaluation of the re-introducing FOLFOX or XELOX ± bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin

2019 Gastric Cancer
Show All
- Source
- Cite
- Save
Citations (8)
A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial

2018 Cancer Letters
Show All
- Source
- Cite
- Save
Citations (9)
Survival of second-line irinotecan-based chemotherapy in early relapse patients with gastric cancer after adjuvant chemotherapy: Exploratory subgroup analysis of TRICS trial.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Phase II study of FOLFIRI + ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine (RAINCLOUD).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)